(Reuters) – the pharmaceutical German Bayer conducted an
offer not binding for the business of animal health of your couple
Pfizer, even though he is considered more likely a split of
that unit, reported a German newspaper in an article that will be
published in the Friday Edition.
The offer of Bayer is based on incomplete data and is
in its early stages, reported the Financial Times Deutschland,
citing a letter sent to members of the Supervisory Board by
Executive President of Bayer, Marijn Dekkers.
Pfizer’s President, Ian Read, said in an interview to
Reuters on Monday that was most likely a split of the unit
animal health before a sale.
Rumors about a possible sale of the unit to
according to several analysts would have an approximate value of
15,000-20,000 million dollars, were fed in the
last week by reports that Novartis AG had made a
offer that was rejected by Pfizer, and Bayer was
probing financing options.
Bayer, the largest pharmaceutical of Germany, declined
statements on Thursday on the report.
